Literature DB >> 16213704

ETS transcription factors and their emerging roles in human cancer.

Arun Seth1, Dennis K Watson.   

Abstract

Cancer can be defined as a genetic disease, resulting as a consequence of multiple events associated with initiation, promotion and metastatic growth. Cancer results from the loss of control of cellular homeostasis. Cell homeostasis is the result of the balance between proliferation and cell death, while cellular transformation can be viewed as a loss of relationship between these events. Oncogenes and tumour suppressor genes act as modulators of cell proliferation, while the balance of apoptotic and anti-apoptotic genes controls cell death. All cancer cells acquire similar sets of functional capacities: (1) independence from mitogenic/growth signals; (2) loss of sensitivity to "anti-growth" signals; (3) evade apoptosis; (4) Neo-angiogenic conversion; (5) release from senescence; and (6) invasiveness and metastasis. One of the goals of molecular biology is to elucidate the mechanisms that contribute to the development and progression of cancer. Such understanding of the molecular basis of cancer will provide new possibilities for: (1) earlier detection as well as better diagnosis and staging of disease with detection of minimal residual disease recurrences and evaluation of response to therapy; (2) prevention; and (3) novel treatment strategies. We feel that increased understanding of ETS-regulated biological pathways will directly impact these areas. ETS proteins are transcription factors that activate or repress the expression of genes that are involved in various biological processes, including cellular proliferation, differentiation, development, transformation and apoptosis. Identification of target genes that are regulated by a specific transcription factor is one of the most critical areas in understanding the molecular mechanisms that control transcription. Furthermore, identification of target gene promoters for normal and oncogenic transcription factors provides insight into the regulation of genes that are involved in control of normal cell growth, and differentiation, as well as provide information critical to understanding cancer development. This review will highlight the current understanding of ETS genes and their role in cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16213704     DOI: 10.1016/j.ejca.2005.08.013

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  174 in total

1.  Thrombocytopenia in mice lacking the carboxy-terminal regulatory domain of the Ets transcription factor Fli1.

Authors:  Omar Moussa; Amanda C LaRue; Romeo S Abangan; Christopher R Williams; Xian K Zhang; Masahiro Masuya; Yong Z Gong; Demetri D Spyropoulos; Makio Ogawa; Gary Gilkeson; Dennis K Watson
Journal:  Mol Cell Biol       Date:  2010-09-07       Impact factor: 4.272

2.  Genome-wide analysis of CDX2 binding in intestinal epithelial cells (Caco-2).

Authors:  Mette Boyd; Morten Hansen; Tine G K Jensen; Anna Perearnau; Anders K Olsen; Lotte L Bram; Mads Bak; Niels Tommerup; Jørgen Olsen; Jesper T Troelsen
Journal:  J Biol Chem       Date:  2010-06-15       Impact factor: 5.157

3.  Cancer: Oncogenes in context.

Authors:  Michael C Heinrich; Christopher L Corless
Journal:  Nature       Date:  2010-10-14       Impact factor: 49.962

4.  Differentiation of carbon dioxide-sensing neurons in Caenorhabditis elegans requires the ETS-5 transcription factor.

Authors:  Manon L Guillermin; Michelle L Castelletto; Elissa A Hallem
Journal:  Genetics       Date:  2011-09-27       Impact factor: 4.562

5.  Porphyromonas gingivalis promotes invasion of oral squamous cell carcinoma through induction of proMMP9 and its activation.

Authors:  Hiroaki Inaba; Hideyuki Sugita; Masae Kuboniwa; Soichi Iwai; Masakazu Hamada; Takeshi Noda; Ichijiro Morisaki; Richard J Lamont; Atsuo Amano
Journal:  Cell Microbiol       Date:  2013-09-19       Impact factor: 3.715

6.  The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer.

Authors:  Rebecca E Graff; Andreas Pettersson; Rosina T Lis; Natalie DuPre; Kristina M Jordahl; Elizabeth Nuttall; Jennifer R Rider; Michelangelo Fiorentino; Howard D Sesso; Stacey A Kenfield; Massimo Loda; Edward L Giovannucci; Bernard Rosner; Paul L Nguyen; Christopher J Sweeney; Lorelei A Mucci
Journal:  Prostate       Date:  2015-03-01       Impact factor: 4.104

7.  Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.

Authors:  Maisa Yoshimoto; Anthony M Joshua; Susan Chilton-Macneill; Jane Bayani; Shamini Selvarajah; Andrew J Evans; Maria Zielenska; Jeremy A Squire
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

8.  TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions.

Authors:  Nuno Cerveira; Franclim R Ribeiro; Ana Peixoto; Vera Costa; Rui Henrique; Carmen Jerónimo; Manuel R Teixeira
Journal:  Neoplasia       Date:  2006-10       Impact factor: 5.715

9.  Regulators of gene expression as biomarkers for prostate cancer.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

10.  Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients.

Authors:  Ali Ghadersohi; Kunle Odunsi; Shaozeng Zhang; Rami G Azrak; Brian N Bundy; Masoud H Manjili; Fengzhi Li
Journal:  Int J Cancer       Date:  2008-09-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.